{'fraction_non_alphanumeric': 0.04286946259985476, 'fraction_numerical': 0.02183188090050835, 'mean_word_length': 4.807195571955719, 'pattern_counts': {'":': 0, '<': 13, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mitochondria-targeted alginate/triphenylphosphonium-grafted-chitosan for treatment of hepatocellular carcinoma

Mitochondrial targeting of anticancer drugs can effectively eradicate chemotherapy-refractory cells through different mechanisms. This work presents the rational designing of mitochondria-targeted core–shell polymeric nanoparticles (NPs) for efficient delivery of doxorubicin (DOX) to the hepatic carcinoma mitochondria. DOX was electrostatically nano-complexed with sodium alginate (SAL) then coated with mitotropic triphenylphosphonium-grafted chitosan (TPP+-g-CS) nanoshell. Polyvinyl alcohol (PVA) was co-solubilized into the TPP+-g-CS solution to enhance the stability of the developed NPs. The optimum NPs formula is composed of TPP+-g-CS (0.05% w/v) coating a DOX-SAL core complex (0.05% w/v), with 0.2% PVA relative to CS (w/w). The optimum NPs attained an entrapment efficiency of 63.33 ± 10.18%; exhibited a spherical shape with particle size of 70–110 nm and a positive surface charge which enhances mitochondrial uptake. FTIR and DSC studies results were indicative of an efficacious poly-complexation. In vitro biological experiments proved that the developed mitotropic NPs exhibited a significantly lower IC50, effectively induced apoptotic cell death and cell cycle arrest. Moreover, the in vivo studies demonstrated an enhanced antitumor bioactivity for the mitotropic NPs along with a reduced biological toxicity profile. In conclusion, this study proposes a promising nanocarrier system for the efficient targeting of DOX to the mitochondria of hepatic tumors.


Introduction
Hepatic cancer has reached a daunting record for mortality rates counting for 8.3% of the total cancer deaths occurring in 2021 as reported by GLOBOCAN. 1 The mainstream for liver cancer treatment protocols relays at an early stage on surgery and drug chemotherapy. Despite the clinical advances achieved by such therapies, diverse drawbacks still hamper their curative efficacy. These include for instance the disease recurrence as well as the high metastasis rates encountered post-surgical resection of tumor masses. Additionally, in case of chemotherapy, the non-selective nature of drugs used can cause severe systemic toxicity leading to hazardous health effects. Therefore, the development of targeted antitumor drug platforms with maximal therapeutic activity concomitantly with minimal toxic side effects became imperative.
Recently, the application of nanomedicine in the treatment of various diseases is an expanding eld of research. Advances in nanotechnology have profoundly beneted the biomedical as well as the pharmaceutical elds as it paved the road for modifying the drug's pharmacokinetic properties including solubility, bioavailability, diffusivity and release prole. 2 Consequently, the deployment of such nanostructured agents can lead to the betterment of their pharmacotherapeutic efficacy through improving the drug's biodistribution and cellular uptake, reducing the dose required and guarding against excessive drug metabolism. 3,4 The optimal design for the nanoscaled vehicle is principally based on the biophysical as well as biochemical properties of the loaded cargo. 5 Growing attention has be drawn towards the development of targeted drug delivery systems (TDDS) as it promote the accumulation of the loaded drugs at the desired site of action and ensuring their selective spatiotemporal release hence enhancing their therapeutic efficacy while reducing any undesirable effects. 6,7 Most TDDSs have relied on the cellular biochemical distinctions between cancerous cells and their normal counterparts like the overexpression of specic surface receptors or antigens hence guarantying their specic recognition, interaction and uptake within the tumor mass. 8 Despite of the selective cellular deliverance, cellular-level targeting alone cannot ensure an enhanced therapeutic efficacy. 9 Thus, recently, subcellular TDDSs that are directed towards certain subcellular compartments have garnered scientic interest. 10 Among the various targetable intracellular organelles, we have chosen mitochondria as it signicantly regulates the cellular homeostasis. Mitochondria control multiple physiological processes namely cellular respiration, metabolism, signaling, differentiation, apoptosis and intracellular Ca 2+ levels. 11 To date several classes of mitotropic ligands were developed for targeting purposes including lipophilic cations namely dequalinium (DQA) and triphenylphosphonium (TPP + ). 12,13 Chemically, TPP + exhibits a unique structure composed of lipophilic phenyl groups as well as a phosphonium cation which endue it with specic mitochondrial accumulation. 14 The discovery of TPP + led to the formation of a plethora of mitotropic drug-conjugates as well as DDS. 15,16 Interestingly TPP + belongs to a class of salts known as quaternary phosphonium salts (QPS) which were reported to have antitumor effects against diverse cancer types including liver cancer. 17,18 Moreover, TPP + was found to preferentially amass in the tumor derived mitochondria due to their higher transmembrane potentials relative to their normal counterparts imparting it with advantageous therapeutic selectivity. 19 Besides the targeting ligand, we have adopted doxorubicin (DOX) to be the model chemotherapeutic agent in this study. Intriguingly, DOX has been reported to act as a mito-active cytotoxic agent with the capability of mitochondrial accumulation aided by its specic binding to the phospholipid cardiolipin. Such DOX-mediated membrane perturbation inhibits complexes I and II deranging the electron transport chain (ETC) function. Additionally, the CI mediated reduction of the quinone moiety in the chemical structure of DOX into a reactive semiquinone free radical can derive the production of the deleterious reactive oxygen species (ROS) creating a vicious iteration of reactions known as the "redox cycling". Alternatively, DOX can further enhance ROS formation via interacting with iron to form reactive anthracycline-iron complexes through Fenton's reactions which ultimately disrupts normal iron homeostasis. Moreover, DOX can produce another class of reactive nitrogen species (RNS) via binding to endothelial nitrogen oxide synthase (eNOS) enhancing its activity which results in peroxynitrite (ONOO À ) free radical formation. Lastly, the mitochondrial DNA (mtDNA) repair enzyme, topoisomerase isoenzyme 1 is one of the main biotargets inhibited by DOX which leads to mitochondrial damage and cell death. 20 Thus, in the present work, TPP + was selected as a mitochondria-targeting moiety and was conjugated to the hydrophilic chitosan (CS) polymer (TPP + -g-CS). Then, mitochondriatargeted core-shell nanoparticles (NPs) were developed and optimized for efficient delivery of doxorubicin (DOX) to the liver mitochondria. Cationic DOX salt was electrostatically nanocomplexed with the negatively charged sodium alginate (SAL) followed by coating the obtained nanocore with the mitotropic TPP + -g-CS nanoshell. Polyvinyl alcohol (PVA) was co-solubilized into the TPP + -g-CS solution to improve the stability of the developed nanosystem. Besides, the obtained DOX-loaded coreshell NPs were optimized in such a way to have a net positive charge enhancing their delivery across the mitochondrial membrane.
Next, the physicochemical, biological, morphological, and drug-encapsulating characteristics of drugfree and drug-loaded NPs were evaluated. Finally, the antitumor effect of TPP + -decorated core-shell NPs against hepatocellular carcinoma was also investigated at both in vitro and in vivo levels.

Preparative procedure
3.1.1. Synthesis of TPP + -g-CS polymer. The polymer preparation steps were inspired by the protocol developed by Huang et al. with few amendments. 21 Briey, LMWT-CS (100 mg) was added to HCl-acidied water (100 ml, pH ¼ 2.25) and le to stir until complete dissolution took place. Meanwhile, the TPP + was activated for 2 h using EDC/NHS aqueous solution. The activated TPP + solution was then centrifuged (10 000 rpm, 15 min) to remove excess EDC/NHS. Aerwards, pellet was resuspended in ultra-pure water and the TPP + solution was dropped onto the CS solution for which pH is adjusted to 4.7 using 1 N NaOH and le to stir over-night on ice (molar ratio 2 : 1 CS : TPP + ). Aerwards, the solution pH is raised to reach 9 using 1 N NaOH leading to precipitation of the graed CS polymer which is inturn collected via ultra-high-speed centrifugation (20 000 rpm, 20 min). The obtained pellet was washed twice with distilled water (2 cycles Â 5 min) and centrifuged. Aerwards, the collected pellet was resuspended in water pH 4.7, frozen and freeze dried (brownish yellow powder).
3.1.2. Synthesis of the DOX-loaded NPs. The NPs were prepared following similar protocol to that reported previously with several modications. 22,23 TPP + -g-CS polymer was dissolved in 1% v/v acetic acid aqueous medium to obtain either 0.05 or 0.1% w/v solution. For polycomplexation, SAL polymer solution was prepared (0.1%, pH ¼ 5.5). Also, DOX solution was prepared with the required concentration (1 mg mL À1 , pH ¼ 8 using TEA). Firstly, DOX was introduced in a dropwise fashion to the SAL solution (ratio ¼ 1 : 1 v/v) resulting in complex formation. Next, the formed complex solution was mixed into the TPP + -g-CS polymer solution up on dropwise addition (ratio ¼ 1 : 2 v/v) under homogenization to reach the desired nal drug concentration. To increase the stability of the developed NPs, TPP + -g-CS polymer was dissolved in PVA containing aqueous solution (0.2% w/w relative to CS) and the above scheme is repeated. Thus, four formulations F1-F4 were obtained as displayed in Table 1.

Structural validation of TPP + -g-CS
3.2.1. Proton nuclear magnetic resonance ( 1 H NMR). The sample was prepared by dissolving of TPP + -g-CS conjugate (10 mg) in DMSO-d 6 1 H NMR spectra were recorded at ambient RT on a JEOL EX300 300 MHz NMR spectrometer (Bruker Avance 300, Coventry, UK).

Fourier transform infrared (FTIR).
The functional groups elucidation of TPP + -g-CS conjugate was determined by FTIR spectroscopy scanning the frequency range of 600-4000 cm À1 (Frontier IR, PerkinElmer, USA).
3.2.3. Differential scanning calorimetry (DSC). The thermal behavior of NP's individual component was investigated using DSC including CS polymer, TPP + pristine powder and TPP + -g-CS polymer (Pyris 6 DSC, PerkinElmer, USA). Samples were enclosed inside sealed standard aluminum pans and exposed to heat in a range of 40-400 C at 10 C min À1 increments. Samples were constantly purged with dry nitrogen at a rate 30 mL min À1 . An empty pan subjected to the same conditions was used as a reference.
3.3. Evaluation of the prepared core-shell NPs 3.3.1. Physicochemical characterization of NPs (FTIR and DSC). FTIR analysis was performed following the aforementioned operating protocol. The experiments were done on CS, plain drug and selected NPs. Moreover, DSC analysis was used to analyze plain DOX, blank NPs and DOX-loaded NPs.
3.3.2. Morphological examination of NPs. Transmission electron microscopy (TEM) was used for the morphological examination of selected NPs. A drop of the nanosuspension was placed onto a carbon coated copper grid, stained, and dehydrated using ethanol then visualized.
3.3.3. Particle size (PS), polydispersity index (PDI) and zeta potential (ZP) measurement. The PS, PDI as well as the ZP of the freshly prepared diluted core-shell NPs nanosuspension was evaluated by dynamic light scattering (DLS) spectroscopy using Malvern zetasizer. For each preparation, measurements were run in triplicates and mean values were recorded.
3.3.4. Drug entrapment efficiency (EE%). The amount of DOX entrapped inside the NPs was evaluated using the indirect assessment method. Where, the freshly prepared drug-loaded NPs were centrifuged (20 000 rpm, 30 min) at RT until complete pelleting of the NPs and separation from the rest of the solution (supernatant).
The concentration of DOX in the obtained supernatant was determined spectrophotometrically. All the measurements were repeated thrice. The drug EE% was mathematically estimated as follows: EE ð%Þ ¼ ðDOXÞ total À ðDOXÞ non-entrapped ðDOXÞ total Â 100 (1) where, (DOX) total denotes the theoretical weight of DOX initially added while (DOX) non-entrapped designates the amount of DOX remaining freely soluble in the supernatant. 3.3.5. In vitro drug release studies. Drug release experiments from DOX-SAL/TPP + -g-CS NPs were run using a dialysis method. In brief, the cellulose membrane (MW cut-off ¼ 12 000 Da; Severa) was hydrated overnight. Aerwards, the membrane was soaked in PBS for 1 h before the start of the experiment. Accurately weighed 10 mg of the dried NPs were reconstituted in PBS (2 mL) with adjusted pH. Next, the reconstituted sample was transferred into an Eppendorf tube, sealed tightly with the dialysis membrane and inverted upsidedown into the receiving chamber. A 50 mL falcon tube (receptor compartment) was lled with 10 mL of PBS adjusted at specic pHs either to mimic the physiological environment (pH ¼ 7.4) or the tumor microenvironment (TME, pH ¼ 6.5). The entire system was continuously shaken (100 rpm, 37 C). One mL aliquot was drawn from the receptor compartment at predetermined time points and the concentration of DOX released from the NPs was determined spectrophotometrically. The withdrawn sample volume was replenished with fresh release medium to keep the volume inside the receptor compartment constant during the entire experiment.
The cumulative percentage of DOX released at a particular time (t) can be calculated using the following equation: where, (DOX) tp is the mass of the cumulative amount of released drug at specic time point and (DOX) total is the total mass of entrapped drug. As controls, blank NPs were used, and the plain drug solution was deployed for comparison rationale applying the same above-mentioned procedure.
3.3.6. Drug release kinetics. The in vitro release data were tted in different mathematical models to investigate the drug release kinetics utilizing the KinetDS soware (version 3.0). 24 3.4. In vitro biological analysis 3.4.1. Cell culture conditions. Human hepatic carcinoma cells (HepG2) were obtained from ATCC (American Type Culture Collection, VA, USA). Cells were grown in DMEM media supplemented with penicillin-streptomycin antibiotics (1%) and fetal bovine serum (FBS, 10%) under humidied CO 2 atmosphere (5% v/v, 37 C).
3.4.2. In vitro cytotoxicity assay. Cytotoxicity assessment of the developed DOX-SAL/CS NPs (F2 0 ) and DOX-SAL/TPP + -g-CS NPs (F2) was done using MTT assay. First, HepG2 cells were seeded into 96-well plate (10 4 cells per well) and incubated overnight. Aerwards, aliquots of NP's suspension, in complete cell culture medium (100 mL), containing DOX at a desired concentration range (0.01, 0.1, 1, 10, 100 mM) were applied to the cells and le to incubate for 48 h. Next, MTT solution (20 mL) was added to each well, mixed and incubated for 5 h. Finally, to assess viable cell count, absorbance peaks of the solubilized formazan dye was spectrophotometrically estimated (l max ¼ 560 nm, corrected for background signals occurring at l max ¼ 620 nm). Additionally, HepG2 cells were incubated with SAL/TPP + -g-CS NPs (as a negative control) using comparative NPs weight to their drug loaded counterparts and the rest of the experiment proceeded following similar procedures to the section above.
3.4.3. Tracking of NPs cellular uptake with uorescence microscopy. To track the intracellular location of DOX-SAL/ TPP + -g-CS NPs (F2), Hep-G2 cells (0.25 Â 10 6 ) were cultured on alcohol sterilized coverslips and incubated overnight to adhere. Aerwards, cells treatment with drug-loaded NPs (DOX concentration ¼ 5 mM) was carried out for 12 h. Post treatment, the cell culture medium was washed away, and the cells were rinsed thrice using cold PBS (pH ¼ 7.4). Aerwards, samples were dyed with MitoTracker Green FM (100 nM, 30 min, 37 C) followed by DAPI nuclear staining (5 min). Cells were washed between different staining steps using cold PBS to eliminate excess dyes. Finally, viable cells were imaged using uorescence microscopy (LABOMED uorescence microscope LX400, cat no:9126000; USA). Image analysis was done using image-J soware.
3.4.4. Measurement of cellular apoptosis. HepG2 cells (10 6 ) were treated with DOX-SAL/TPP + -g-CS NPs (F2) for 48 h, a nontreated group was employed as a negative control. Aer treatment, cells were collected, rinsed with cold PBS (pH ¼ 7.4) and resuspended in 400 mL calcium containing binding buffer. Next, Alexa-Fluor 488 annexin V/propidium iodide staining solution (Probes Invitrogen, Eugene, OR, USA) was applied to the cell suspension (15 min, dark conditions). Post-incubation, the cells (20 000 events per sample) were collected and analyzed in a FACScan ow cytometry analyzer. Excitation (l ¼ 488 nm) and the emission green uorescence of AV (FL 1 , l ¼ 530 nm, x-axis) and red uorescence of PI (FL 2 , l ¼ 575 nm, y-axis) were collected, respectively. Later, the obtained data were analyzed using the ow cytometry analysis soware WinMDI 2.8.
3.4.5. Cell cycle analysis. DOX-SAL/TPP + -g-CS NPs (F2) were applied on HepG2 cells (10 6 ) for 48 h, a non-treated group was employed as a negative control. Aerwards, cells were harvested, washed and xed using cold ethanol (70% v/v) and kept on ice (30 min). Next, cells are collected, washed with cold PBS (pH ¼ 7.4) and centrifuged (300-400 Â g for 5 min). The obtained cell pellet is incubated in nucleic acid staining solution (500 mL, 30 min, RT). Next, one drop of ReadiDrop™ PI was added to the cells yielding a nal dye concentration of 1 mg mL À1 . Finally, the cells were incubated for 10 min followed by analysis using ow cytometry.

3.5.
In vivo biological studies 3.5.1. Animals. Adult Male, CD 1 mice (average weight ¼ 25-30 g) were purchased from laboratory animal facility, Pharmacology and Chemistry Research Centre (PCRC), Misr University and Technology Park, 6 th October City, Egypt. Before starting the experiment, the mice were acclimated for 10 days under 12 h light/dark cycles, controlled humidity, controlled temperature (22 AE 2 C) and ad libitum feeding. The Institutional Animal Care and Use Committee, Fayoum University approved all in vivo experimental procedures with permit number (AEC 2102).
3.5.2. Induction of hepatocellular carcinoma (HCC). HCC was induced by intraperitoneal injection of N-nitrosodiethylamine (DEN, 200 mg kg À1 ) in addition to subcutaneous injection of the tumor-inducing hepatotoxin carbon tetrachloride (CCl 4 , 3 mL kg À1 ) for six consecutive weeks. A total of 30 male CD 1 mice were randomly assigned to 6 groups. The rst group (G 1 ) wild type and served as the negative control for the study. Otherwise, the remaining ve groups (G 2 -G 6 ) received intraperitoneal injection of DEN along with CCl 4 .
3.5.3. Experimental design. Thirty male CD 1 mice were randomly assigned to 6 group (5 mice per group) as follows for ten weeks: Group (1): served as non-treated control and received normal saline only (negative control).
Group (3): animals were treated with SAL/TPP + -g-CS NV carrier system, which is similar in composition to (F2) two times weekly for last consecutive 4 weeks. The aim of G 3 is to investigate the biological toxicity as well as the biological effect of the nanocarrier perse.
Group (4): mice were treated with DEN + CCl 4, then treated with free DOX$HCl (5 mg kg À1 , i.p) two times weekly for the last consecutive 4 weeks.
The results obtained from G 5 would confer a comparative stance to G 6 about the biological toxicity prole as well as the therapeutic efficiency of DOX-loaded mitochondrial NPs versus non-targeted counterparts.
3.5.4. In vivo serological tests. At the end of treatment period aer 10 weeks, mice were anesthetized using ketamine (12.5 mg kg À1 ) and xylazine (1.5 mg kg À1 ). Aerwards, blood samples were collected from each mouse from retro-orbital vein under using non-heparinized microhematocrite capillary tubes and allowed to clot at RT. Next, samples underwent centrifugation (3000 xg, 20 min) to separate the serum and got stored at À20 C until being used for serological assay. Treatment efficiency was monitored by measuring the tumor biomarker afetoprotein levels (AFP) using ELISA kit (Anogen, Mississauga, Ontario, Canada). Moreover, hepatic biomarkers levels namely alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were evaluated using colorimetric kit (ProDia international, Germany). Whereas the serum level of the hepatic biomarker alkaline phosphatase (ALP) was estimated using kit (Biolabo SA, France).
3.5.5. In vivo histopathological examination. Animals will be euthanized under light anesthesia and their liver will be removed for histological examinations. Liver tissue specimens collected from various treatment groups were xed in 10% neutral buffered formalin. Next, the xed hepatic specimens were trimmed, washed, dehydrated in ascending grades of alcohol, cleared in xylene and embedded in paraffin. Aerwards, the specimens were sectioned (4-6 mm thickness) and stained by hematoxylin and eosin (H&E) for further microscopic investigation using light microscopy.

Statistical analysis
The statistical analysis was done using one-way Anova followed by Tukey's test (Sigma plot soware 11.0). Statistical differences with (P # 0.001) denote extreme signicance, (P # 0.01) denotes high signicance and (P # 0.05) indicates statistical signicance. Data were represented as mean AE SD.

Preparation of TPP + -g-CS conjugate
The TPP + -g-CS conjugate was prepared as demonstrated in chemical synthesis Scheme 1. Initially, TPP + carboxylic group was activated through its reaction with the coupling reagents EDC.HCl followed by NHS thus forming an amine-reactive Oacyl-isourea intermediate then the more stable amine-reactive NHS ester, respectively. Subsequently, the produced NHS ester was added to an acidied aqueous solution of CS-polymer yielding the nal desired conjugate (TPP + -g-CS) connected via a stable amidic bond. The graed polymer was collected through centrifugation followed by lyophilization (brownish yellow powder).

Structural validation of TPP + -g-CS
1 H NMR spectrum of TPP + -g-CS is shown in Fig. 1. Conjugation was affirmed due to the presence of signals between 7.80 and 8.57 ppm appearing at the aromatic region of the spectrum which are pertinent to the three phenyl rings of the newly introduced triphenylphosphonium groups. 25,26 However, the signals of the methylene protons in TPP + could not be distinguished clearly due to their relatively lower intensity and overlapping with the CS peaks at the aliphatic region of the spectrum.
FTIR spectra of TPP + -g-CS, TPP + , and CS from 500 to 4000 cm À1 are depicted in Fig. 2a. In TPP + -g-CS, there was a new absorption peak presenting at 1548 cm À1 corresponding to the Scheme 1 Chemical synthesis steps of TPP + -g-CS conjugate. absorption bands of the C]C of the phenyl rings pertinent to TPP + moiety. 25 Moreover, compared to the spectrum of CS, the appearance of additional peaks at 1640 cm À1 in the spectrum of TPP + -g-CS, demonstrating that carboxylic group of TPP + mainly reacted with the amino groups of CS to form an amide bond. 27 DSC thermograms are shown in Fig. 2b. First the CS chart demonstrated an endothermic peak at 109 C indicating loss of hydration water as well as an exothermic signal at 236 C indicative of the thermal decomposition of amine units in CS chains. As for the TPP + cation thermogram, two endothermic peaks at 250 C (sharp) and 350 C due to its melting and decomposition, respectively. Comparing the conjugate chart to its respective precursors, the bimodal endotherm at 124 C with a fused shoulder 236 C conrms the proper conjugation process. The observed decrease in intensity of endothermic peak at 125 C, may indicate a reduction in the amount of water bound to the CS polymer post-conjugation due to consumption of free amino groups. Moreover, the broad endothermic peak at 352 C can be attributed to the decomposition of TPP + moiety linked in the conjugate. Besides, the observed exothermic signal at 294 C correlates to the residual unconjugated amine groups in CS backbone.

Particle size, surface charge and entrapment efficiency
Results of the particle size, surface charge and entrapment efficiency experiments are displayed in Table 2. It can be inferred from the obtained results that the presence of the PVA partially shielded the surface charge of the TPP + -g-CS rendering it less positive, this observation is similar to previous literature. 28 PVA shielding of surface charge in turn affected particle size creating an observable pattern. Where, the highly positive NPs lacking PVA (F1 and F3) tend to be unstable resulting in relatively high aggregate PS and widely distributed PDI. On the contrary, PVA addition to NPs (F2 and F4) increased their stability and reduced their PS thus yielding a more homogenous population. Another pattern seen amongst PVA lacking NPs (F1 and F3), is the direct proportionality of the PS to the CS percentage used; an effect that got moderated aer PVA addition. Also, the drug entrapment followed a noticeable pattern, where the EE% increased with PVA addition (F2 and F4) relative to the rest of the developed NPs (F1 and F3). The observed results might be attributed to increased NPs stability. From the obtained results of physicochemical characterization F2 formula was considered optimum and hence was selected for further studies.

Morphological investigation (TEM images)
TEM images of the DOX-SAL/TPP + -g-CS NP (F2) demonstrated that the particles exhibited a spherical morphology with the size range (80-110 nm). The observed NPs size was lower than that measured using DLS. DLS obtained results might reect the hydrated particle size (372 nm with PDI values 0.391), Fig. 3. As reported repeatedly, TEM imaging is considered the technique of choice to accurately assess NP's PS as it depends on direct high-resolution visualization of particles. Moreover, artifacts affecting the quality of DLS measurements including solution dynamics, NPs aggregation, presence of hydration shells by the surrounding solvent as well as Brownian motion induced uctuation in light-scattering are well eliminated. 29 Therefore, PS obtained by TEM imaging were selected over DLS.

Physicochemical characterization of NPs
The absorption spectrum for pristine DOX shows a characteristic band at 1722 cm À1 (C]O bond stretching) at atom C-13.
The peaks occurring at both 1575 and 1615 cm À1 (C]O bond stretching and bond vibration) of the anthracene ring, respectively. Moreover, the wide band observed at 3360 cm À1 signals overlapped peaks (-OH and -NH 2 groups vibration). As for DOX-SAL/CS NPs chart, the peak at 3298 cm À1 is similarly present in the parent TPP + -g-CS and the nanovoid (NV) conrming proper formation of NPs. Moreover, the disappearance of 3360 cm À1 related to the pristine DOX conrms the effective physical entrapment of the drug inside the NPs, Fig. 4a. Additionally, the occurrence of peaks at 1588 and 1405 cm À1 were observed. Conclusively, FT-IR charts indicate the electrostatic interactions between DOX, SAL and CS. DSC was employed to understand the thermal behavior of the developed DOX-SAL/CS NPs and to elucidate possible interactions between the different constituting polymers along   with the drug. Generally, the endothermic peaks around 100 C are mainly associated with the dehydration of the hydrophilic molecules. The obtained thermograms demonstrate a minor lowering in the melting endotherm observed in the developed NPs relative to pristine TPP + -g-CS polymer which conrms the formation of NPs. Furthermore, comparing the thermogram of NVs to that of DOX-loaded CS NPs reects the disappearance of the endothermic peak at 293 օ C as well as the step change at 377 C suggesting that the electrostatic interactions occur between DOX, the carboxylic groups of SAL and the aminogroups of CS. Moreover, DOX-loaded NPs thermogram was showing a minor endothermic peak at 207 C that might be DOX-related endothermic melting peaks indicating the proper inclusion of drug in the polymer, Fig. 4b.

In vitro drug release experiments
The prepared DOX-loaded core-shell NPs (F2) revealed a sustained release prole of the drug that lasted for 168 h, Fig. 5. Moreover, the results demonstrated that the cumulative drug release rate was signicantly greater at the TME mimicking acidic environment (pH ¼ 6.5) in comparison to physiological conditions (pH ¼ 7.4), P < 0.05. The obtained ndings suggest that there is a relative spatial selectivity in drug release within the cancerous niche.
To completely comprehend the kinetics of drug release, the empirical results were tted using mathematical modeling, Table 3. Modeling outcomes showed that all the tested NPs predominantly followed the Korsmeyer-Peppas model pertinent to polymeric systems (R 2 ¼ 0.999). Where, the numerical value of the diffusional exponent (n) can predict the drug-release mechanism. Conventionally, Fickian diffusion is represented by (n # 0.5) whereas, non-Fickian model can be either anomalous transport (0.5 < n < 1), case-II transport (n ¼ 1) or super case-II transport (n > 1). 30 Conclusively, the obtained release exponent n > 1 reects a non-Fickian drug release follows super case-II transport that is controlled through polymer swelling and relaxation. 4.7. Biological assessments 4.7.1. Cytotoxicity results. To determine the cytotoxic concentration of the TPP + -g-CS based NPs, HepG2 hepatocellular carcinoma cells were treated by the NPs either drug free (as negative control) or drug loaded NPs under the same conditions also non-graed-CS NPs (F2 0 ) and free DOX were tested (as positive controls), Table 4 and Fig. 6. The concentration depicted on the horizontal axis is equivalent to DOX in the NPs and a similar weight of NV was taken as a negative control. From the obtained results it was found that DOX-SAL/TPP + -g-CS NPs (F2) were the most efficient to signicantly reduce cell viability (IC 50 ¼ 3.86 AE 0.20 mM) as compared to the non-graed-CS NPs (F2 0 ) exhibiting 3-fold lower cytotoxicity (IC 50 ¼ 12.94 AE 0.68 mM, P ¼ 0.001). The obtained ndings prove the higher efficiency of mitochondrial targeting in inducing cancer cells death. Furthermore, to test the biocompatibility of the   developed TPP + -g-CS NPs, the NVs were applied to the cells and were proven non-toxic to cells perse. 4.7.2. Fluorescence imaging and cellular uptake results. To track, visualize and quantify the intracellular localization of DOX-SAL/TPP + -g-CS NPs (F2), HepG2 intracellular organelles were dyed with nuclear labelling stain (DAPI, dark blue color) and mitotracker (green color) uorescent dyes, Fig. 7. As shown in microscopic images, F2 NPs were successfully internalized by the treated cells as presented for uorescence pertinent to DOX (red color). Intriguingly, the drug was found to almost exclusively localized in the mitochondria which is evident in the merged eld resulting in yellow pseudo-uorescence. Based on image analysis and areas overlay measurements, red-green areas overlay percentage was found to be 85.299% conrming the extensive mitochondrial uptake of the targeted F2 NPs. On the contrary, red-blue areas overlay was merely 1.074% indicating the poor nuclear localization of the DOX-loaded NPs. 4.7.3. Apoptotic cell death analysis results. Cells undergoing apoptosis can be detected through investigating the inversion of the membrane phospholipid, phosphatidylserine (PS), from the internal membrane side to the external membrane surface. This phenomenon is assessed via costaining the cells with annexin-FITC which binds to the externalized PS and propidium iodide (PI) which exclusively intercalates the DNA of permeable dead cells. Accordingly, HepG2 liver carcinoma cells were subjected to DOX-SAL/TPP + -g-CS NPs (F2) using the reported IC 50 for 48 h. While non-treated cells were deployed as negative control. Results, presented in Table 5 and Fig. 8, show that the treatment elicited apoptotic programmed cell death with signicant 26.08% decline in cell viability (P ¼ 0.001). Early apoptotic sub-population percentage was 3.62%, which is 7.86-fold higher than the non-treated control (P ¼ 0.001). Furthermore, dual stained late apoptotic cells percentage was 14.25% (P ¼ 0.001), which is approximately 55-fold higher than the negative control. Collectively, it can be concluded that the applied optimal NPs effectively elicited programmed cell death in HepG2 cells. Besides, a signicant increase in necrotic sub-population was observed counting for 9.54% which is almost 16-fold higher than their non-treated counterparts (P ¼ 0.001). 4.7.4. Cell cycle analysis results. The treatment elicited changes in the cellular distribution among different cell-cycle   phases was investigated via implementing the DNA content ow cytometric analysis. Results showed that HepG2 cells treated by DOX-SAL/TPP + -g-CS NPs (F2) accumulated at the pre-G1 phase recording an almost 20-fold increase comparative to nontreated control cells. The ndings suggest that the genetic material underwent degradation proving that the NPs have an effective apoptosis mediated anti-proliferative activity (P ¼ 0.001). The results observed conform well with our conclusions inferred from apoptosis analysis. Furthermore, cell-cycle arrest at S-phase was also noticed with 1.65-fold increase in cell population relative to control (P ¼ 0.001) concomitant with a signicant reduction in G2/M-phase population, obtained are similar to previous reports. 21 The obtained result suggests intervention with DNA replication associated with decreased cell-population in the G2/M-phase. Meaning, our DOX-loaded NPs target (4n) S-phase cells at chromosomal replication stage leading to enhanced DNA binding capability leading to inability to ensue to the subsequent phase. Results are displayed in Table  6 and Fig. 9.

4.7.5.
In vivo HCC-induction and biochemical analysis results. Hepatic tumors were induced in the mice using Nnitrosodiethylamine (DEN). a-Feto protein (AFP) measurements in blood were implemented weekly to conrm successful tumor induction, Fig. 10a. The expression of AFP is directly correlated with hepatocyte differentiation and is considered as the standard noninvasive diagnostic biomarker for HCC progression. 31 Tumor formation took 10 weeks and was further conrmed through histopathological examination of the liver tissues, Fig. 11b. Physiologically, DEN is metabolically bioactivated in the liver to produce O 6 -ethyl deoxyguanosine as well as O 4 -and O 6 -ethyl deoxythymidine. The formed metabolites form irreversible DNA adducts leading to carcinogenesis. 32 Additionally, to ensure proper initiation of HCC the hepatotoxin carbon tetrachloride (CCl 4 ) was introduced. Mechanistically, CCl 4 increases the endotoxin levels which promote the development of hepatic inammation and brosis that are reportedly mediated by the ROS activation and biochemical signaling aberrations. 33 As a tumor promoter, CCl 4 reduces the time required for tumor formation. 34 The obtained ndings demonstrated severe liver damage of AFP signicant protein level increase postinjection with hepatotoxins DEN + CCl 4 relative to normal group (P < 0.0001). A signicant incremental decrease in AFP level was observed upon treatment with free DOX.HCl, as compared to the normal control (P < 0.05). Remarkably, G 5 and G 6 treated with non-graed-CS NPs (F2 0 ) and TPP + -g-CS NPs (F2) reverted to normal physiological AFP serum levels. Since several studies conrmed a direct proportional relation between serum AFP and severity of liver disease clinically, it can be concluded that F2 possesses the most therapeutic efficiency. 35 Post tumor induction, a dose titration study was implemented to gure out the effective lethal dose (EC 50 ) of the free DOX.HCl (G 4 ) as well as the DOX-loaded core-shell NPs (G 5 , G 6 ). The obtained ndings showed that both the free drug (G 4 ) and non-graed-CS NPs (F2 0 , G 5 ) had similar EC 50 values of (5 mg kg À1 ) resulting in the death of 50% of the animal test population. Intriguingly, the attained EC 50 of the TPP + -g-CS NPs (F2, G 6 ) was signicantly lower than the ungraed NPs (P < 0.001) equivalent to (2.5 mg kg À1 ). The last observation is reminiscent of the in vitro cytotoxicity study affirming the Fig. 10 Assessment of the antitumor effect and biological toxicity of DOX-SAL/CS core-shell NPs using hepatocellular carcinoma (HCCbearing) in vivo animal model (a) AFP hepatic protein level, (b) ALT hepatic enzyme activity, (c) AST hepatic enzyme activity, (d) ALP hepatic enzyme activity, and (e) troponin-T cardiac protein level. Results presented as mean AE SD (n ¼ 9), statistical significance is relative to control ( a P # 0.05, b P # 0.01, c P # 0.001, d P # 0.0001). enhanced antiproliferative efficiency owing to the mitochondrial targeting.
The evaluation of alanine aminotransferase (ALT) enzyme levels in the serum was investigated to assess the extent of hepatic injury, Fig. 10b. 36 Findings showed that HCC induction procedure in mice caused extreme hepatotoxicity accompanied with signicant increase in serum ALT levels relative to normal mice (P < 0.0001). This hepatotoxic effect was reversed upon treatment with both F2 0 and F2 core-shell NPs. The restoration of normal liver functioning is evident through rendering ALT protein levels similar to the normal serum value. Unlike the DOX-loaded NPs, the treatment with drug free NVs were not able to reverse the HCC pertinent functional aberrations (P < 0.0001). This last nding proves that NVs do not have any antiproliferative activity by itself. Despite, being therapeutically active free DOX was not as efficient as the NPs in restoring the normal ALT levels (P < 0.01).
Likewise, to ALT, enhanced levels of aspartate aminotransferase (AST) protein in the blood is well correlated to hepatic diseases. 37 A similar pattern was observed for AST serum levels to that of ALT before and aer treatment with NPs, Fig. 10c. Additionally, alanine aminotransferase (ALP) serum level, which is used as an HCC prognostic factor, was assessed. 38 The results showed that trend of change in ALP serum level was resembling that of ALT and AST, Fig. 10d. Interestingly, the graed-CS NPs (F2) were signicantly efficient in restoring ALP levels to normal, which is signicantly better when compared to their non-graed counterparts (F2 0 ) (P < 0.01). Our ndings relevant to the reduction of AST and ALP serum levels posttreatment by the developed NPs (F2 and F2 0 ) conrm that they are more therapeutically effective when compared to free DOX.
Beyond their antiproliferative capacity, the developed NPs biological toxicity prole was evaluated. The biological toxicity of the drug is an important aspect of our study as it is well reported that DOX induces severe cardiotoxicity. 39,40 To this end, the cardiotoxicity biomarker troponin-T serum level was measured, Fig. 10e. 41 As shown by the results, treatment by free DOX (G 4 ) caused an extremely signicant cardiotoxicity as compared to normal control (G 1 ) (P < 0.0001). Compared to the free drug, treatment with the developed NPs (G 5 , G 6 ) conferred a reduced biological toxicity prole signicantly lowering the troponin-T levels (P < 0.0001). Taking the dose difference into account, treatment with the mitochondria targeted NPs (G 6 ) was evidently safer than non-targeted NPs (G 5 ) (P < 0.01), attaining similar protein levels to the normal control. 4.7.6. Histopathological examination for liver tissues results. Microscopic examination of mice liver samples from different groups was done as shown in Fig. 11(a-e). Normal control G 1 samples demonstrated normal histological features of mouse liver in parenchyma with many obvious wellstructured hepatocytes with integral subcellular details (arrow), unawed hepatic vasculature (star) and portal areas with undamaged sinusoids were shown, Fig. 11a. Model HCC G 2 samples showed severe disorganization of histological features of hepatic parenchyma with many records of hepatomegaly with many hyperchromatic binucleated cells with prominent nucleoli (red arrow), fewer apoptotic gures were observed accompanied with moderate dilatation of hepatic blood vessels (star) severe mononuclear inammatory cells inltrates all over hepatic lobules and perivascular areas (yellow arrow). Signicant broblastic activity was observed with moderate pseudo lobulation of hepatic lobules by newly formed collagen bers dashed arrow, Fig. 11b. G 3 mice treated with CS NVs showed almost the same records as model sample with milder and nonsignicant decrease of inammatory cell inltrates. Fig. 11c. G 4 mice treated with free DOX.HCl showed mild dilation and congestion of hepatic BVs (star) with persistent record of perivascular inammatory cell inltrates (yellow arrow). Moreover, signicant reduction of inammatory cells inltrates all over hepatic sinusoids minimal broblastic activity as well as minimal records of abnormal hepatocellular changes and alterations with few records of degenerated hepatocytes (red arrow), Fig. 11d. G 5 mice treated with DOXloaded CS NPs (F2 0 ) showed more organized morphological features of hepatic parenchyma with minimal scattered records of cytomegaly with hyperchromatic nuclei (red arrow), Fig. 11e. Moreover, intact vasculatures were shown (star) with minimal inammatory cell inltrates as well as broblastic activity. Finally, G 6 mice treated with DOX-loaded TPP + -g-CS NPs (F2) showed almost intact hepatocellular structures with few scattered degenerated hepatocytes (red arrow). However, moderate dilation of hepatic BVS (star) with mild periportal focal inammatory cell inltrate (yellow arrow) and collagen bers (dashed arrow) were shown, Fig. 11f.
Taken together, the biochemical serological testing as well as the histological examination indicated the superiority of mitochondrial targeting (G 6 ) in effectively inhibiting HCC progression at a signicantly lower dose. Additionally, mitotropic NPs (F2) attained a biologically safe prole with minimized hepatotoxicity to almost null cardiotoxicity.

Conclusion
This study reports the development of mitotropic chitosan/ sodium alginate-based core-shell nanocarriers (DOX-SAL/ TPP+-g-CS NPs) for the treatment of hepatic cancer. The optimum NPs were found to exhibit favorable physicochemical characteristics mainly enhanced structural stability due to the incorporation of PVA; reected by the enhanced drug EE% and homogenous particle size distribution. The other factor contributing to the high EE% is the electrostatic interaction between the cationic DOX with the polyanionic sodium alginate polymer. Aerwards, the mitochondria targeting was ensured through the synthesized TPP + -g-CS polymer used as an outer coating shell. Release proles were also evaluated and were shown to be pH dependent. Biologically, the DOX-SAL/TPP + -g-CS NPs were found to be exclusively localized in the mitochondria, potentiating their antiproliferative activity. In vitro studies proved that the synthesized core-shell NPs were found to cause apoptotic cell-death and S-phase cell-cycle arrest. Finally, the in vivo studies proved that the designed NPs were biocompatible as reected by the reduced cardiotoxicity and the therapeutic efficacy as presented by the retrieval of normal hepatic function and structure. Conclusively, the prepared NP system deems promising due to its enhanced therapeutic selectivity towards cancerous cells nominating it for wider application against various cancer types.

Conflicts of interest
There are no conicts to declare.